LAG3 and neoplasm: It is worth noting that when the interaction between LAG3 and ligand FGL1 is blocked by monoclonal antibodies, the T cell response in the tumor is enhanced and the tumor volume decreases, which provides a new idea for targeted immunotherapy [124].